Latest News and Press Releases

WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American...

Innovative transdermal technology enables delivery of abaloparatide molecule – a peptide - across the skinTrial success followed by regulatory approval would provide a completely unique drug...

WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020. Radius Health management...

TYMLOS® patent extended to 2031, adding approximately 3½ years to the TYMLOS-SC patent lifeEnrollment completed for ATOM Phase 3 study assessing the efficacy and safety of abaloparatide-SC in males...

WALTHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with...

TYMLOS® U.S. net sales of $50 million, with 22% year over year growth Completion of enrollment in ATOM Phase 3 expected this week Phase 3 Trials: wearABLe and EMERALD remain...

WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020. The Company will...

Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 developmentElacestrant further strengthens Menarini’s global oncology...

Radius partner Teijin Pharma has submitted a New Drug Application for abaloparatide-SC for treatment of osteoporosis in Japan   WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc....

TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs...